Skip to main content
. Author manuscript; available in PMC: 2010 Apr 6.
Published in final edited form as: Cancer Cell. 2009 Oct 6;16(4):281–294. doi: 10.1016/j.ccr.2009.08.018

Table 1. Primary Patient AML Characteristics.

Patient Diagnosis Cytogenetic Findings FLT-3 ITD FLT-3 D835 Codon
change
1 M1-AML 89–92, XXXX No No
2 M2-AML 45 XY, −7, inv(3)(q21q26) No No
3 CMML Complex karyotype* N/A N/A
4 M4-AML 46 XY No D835H
5 M4-AML 46 XX No D835E
6 M2-AML 46 XX Yes No
7 M3-AML 47 XX, +8, t(15;17) (q22;q21) Yes No
8 M4-Eo 45 X,−Y[11] / 46, XY[9]. Nuc ish (CBF x2)
[100]
No No
9 M1-AML 46 XX No No
10 M-5b-AML 46 XX No D835Y
11 M4-AML 46 XY Yes No
12 AML** N/A Yes No
13 AML** 46 XY No No
14 M4-AML 46 XY Yes No
15 AML** 47 XX, +8 [19] / 46, XX [1] Yes No
31 M7-AML 52,XY,+8,+14,+19,+21,+21,+21c[14]/
47,XY,+21c[6]
N/A N/A

N/A = not available

*

46, XY, t (1;19) (p36;q13), del (2) (p2?3), t (3;15) (p21;q22), add (4) (q35), −6, der (7) t (7;14) (q36;q11.2), −14, −21 + mar [cp10]/ 46 XY, del (2) (p2?1), add (7) (q11.2) [cp4]/ 46, XY, add (1) (q42), t (1;14) (p12;q11), del (3) (q1?3), der (7) del (7) (q3?1q3?4) t(3;7) (q13;p22, t(17;21) (q2?1;q22) [2]/ 46, XY, non clonal abnormalities [4]

**

FAB not reported

HHS Vulnerability Disclosure